There were no significant differences in age, sex, disease duration, onset times, EDSS score, and the presence of visual disturbance for the MS, AQP4+ NMOSD, and MOGAD groups, respectively, between the development and testing datasets. Here, AQP4 is linked to myeloid sarcoma.